...include testing DP1 inhibitors in the mouse model of ALS. Merck & Co. Inc.'s Cordaptive (MK-0524A...
...testing for atherosclerosis and cardiovascular disease. Merck also has MK-0524B, an extended-release, fixed-dose combination of MK-0524A...

...to be well tolerated in humans," Anthony said. In 2008, Merck & Co Inc. 's Tredaptive...
...Tredaptive, preclinical studies showed that the drug had no CNS exposure. In 2013, Merck withdrew Tredaptive...

...than 3,000 patients. In December 2012, Merck said it would not seek U.S. approval of Tredaptive...

...Merck & Co. Inc. (NYSE:MRK) Says it will suspend the worldwide availability of cardiovascular drug Tredaptive...

...endpoint of coronary death, non-fatal MI, stroke or revascularization occurred in 13.2% of patients receiving Tredaptive...
...and Trevaclyn in Italy and Portugal. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...

...confirmed a recommendation from the agency's Pharmacovigilance Risk Assessment Committee to suspend marketing authorization of Tredaptive...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...

...Merck said it will suspend the worldwide availability of Tredaptive after data from the investigator-led Phase...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...

...Merck & Co. Inc. (NYSE:MRK) said it will suspend the worldwide availability of Tredaptive . The...
...non-fatal serious adverse events. Separately, EMA's Pharmacovigilance Risk Assessment Committee recommended suspending marketing authorization of Tredaptive...
...reviewing Tredaptive in December following the HPS2-THRIVE data (see BioCentury Extra, Dec. 21, 2012) . Tredaptive...

...to treat non-infectious uveitis Merck & Co. Inc. (NYSE:MRK) Will not seek U.S. approval for Tredaptive...

...Phase III HPS2-THRIVE trial in 25,673 patients at high risk for cardiovascular events showed that Tredaptive...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...in January. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive ( MK-0524A...